Filtros de búsqueda

Lista de obras de Michael Wang

"Triple Hit" SOX-11- , CD10+ , TP53 mutated high-grade pleomorphic mantle cell lymphoma

scientific article published on 01 May 2020

2-Chlorodeoxyadenosine (2-CdA) and Cyclophosphamide (Cy) Alone or in Combination with Rituximab (Rit) for Previously Untreated Waldenstrom’s Macroglobulinemia (WM). ⬇️

artículo científico publicado en 2004

A British Society for haematology good practice paper on the diagnosis and investigation of patients with mantle cell lymphoma

artículo científico publicado en 2018

A Phase 2 Study of Prolonged Carfilzomib Therapy in Patients with Multiple Myeloma Previously Enrolled in Carfilzomib Clinical Trials. ⬇️

artículo científico publicado en 2012

A Phase I/II Trial of the KSP Inhibitor ARRY-520 In Relapsed/Refractory Multiple Myeloma ⬇️

artículo científico publicado en 2010

A Phase III study of zanubrutinib plus rituximab versus bendamustine plus rituximab in transplant-ineligible, untreated mantle cell lymphoma

scientific article published on 28 September 2020

A Randomized Phase II Trial of High-Dose Melphalan, Ascorbic Acid and Arsenic Trioxide with or without Bortezomib in Multiple Myeloma. ⬇️

artículo científico publicado en 2009

A phase 1 study of filanesib, carfilzomib, and dexamethasone in patients with relapsed and/or refractory multiple myeloma

scientific article published on 01 October 2019

A phase 1 trial of alisertib and romidepsin for relapsed/refractory aggressive B-cell and T-cell lymphomas

scientific article published on 09 May 2019

A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma

artículo científico publicado en 2012

A phase I study of carfilzomib in combination with ibrutinib for relapsed refractory mantle cell lymphoma

scientific article published on 14 February 2020

A phase I/II trial of the combination of lenalidomide, thalidomide and dexamethasone in relapsed and/or refractory multiple myeloma

artículo científico publicado en 2019

A phase II study of carfilzomib in the treatment of relapsed/refractory mantle cell lymphoma

artículo científico publicado en 2018

A practical guide to achieving and maintaining the best response to lenalidomide in multiple myeloma: roundtable proceedings.

artículo científico publicado en 2007

A randomized phase 2 trial of a preparative regimen of bortezomib, high-dose melphalan, arsenic trioxide, and ascorbic acid

artículo científico publicado en 2011

A severe combined immunodeficient-hu in vivo mouse model of human primary mantle cell lymphoma

artículo científico publicado en 2008

ATF4 induction through an atypical integrated stress response to ONC201 triggers p53-independent apoptosis in hematological malignancies

artículo científico publicado en 2016

ATM mutation and radiosensitivity: An opportunity in the therapy of mantle cell lymphoma

artículo científico publicado en 2016

Acalabrutinib for adults with mantle cell lymphoma

artículo científico publicado en 2019

Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial.

artículo científico publicado en 2017

Acalabrutinib: Managing Adverse Events and Improving Adherence in Patients With Mantle Cell Lymphoma

scientific article published on 01 August 2020

Accelerated therapeutic progress in diffuse large B cell lymphoma

artículo científico

Advances in the assessment of minimal residual disease in mantle cell lymphoma

scientific article published on 24 September 2020

An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma

artículo científico publicado en 2012

An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib

artículo científico publicado en 2012

Analyzing Patient Characteristics Who Received (DA) EPOCH-R for High Risk Diffuse Large B-Cell Lymphoma: MD Anderson Cancer Center Experience ⬇️

scholarly article

Anti beta2-microglobulin monoclonal antibodies induce apoptosis in myeloma cells by recruiting MHC class I to and excluding growth and survival cytokine receptors from lipid rafts

artículo científico publicado en 2007

Anti-CD20 and B-Cell Receptor-Mediated Growth Inhibition and Apoptosis: A Preclinical Study of Ibrutinib and Rituximab Combination Therapy in Mantle Cell Lymphoma in Vitro and in Vivo ⬇️

artículo científico publicado en 2014

Antigen Presenting Cell-Mediated Ex Vivo Expansion of Human Umbilical Cord Blood Cells Yields Log-Scale Expansion of Natural Killer Cells with Anti-Myeloma Activity ⬇️

artículo científico publicado en 2010

Antigen presenting cell-mediated expansion of human umbilical cord blood yields log-scale expansion of natural killer cells with anti-myeloma activity.

artículo científico publicado en 2013

Antitumor activity of a novel STAT3 inhibitor and redox modulator in non-small cell lung cancer cells

artículo científico publicado en 2012

Arsenic Trioxide with Ascorbic Acid and High-Dose Melphalan Is Safe and Effective for Autotransplantation for Multiple Myeloma. ⬇️

scholarly article

Arsenic Trioxide with Ascorbic Acid and High-Dose Melphalan for Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma. ⬇️

artículo científico publicado en 2006

Arsenic trioxide with ascorbic acid and high-dose melphalan: results of a phase II randomized trial

artículo científico publicado en 2008

Asia-Pacific Hematology Consortium Report on approach to multiple myeloma. Survey results from the 6th International Hematologic Malignancies Conference: Bridging the Gap 2015, Beijing, China.

artículo científico publicado en 2016

Assessment of CD37 B-cell antigen and cell of origin significantly improves risk prediction in diffuse large B-cell lymphoma

artículo científico publicado en 2016

Atiprimod inhibits the growth of mantle cell lymphoma in vitro and in vivo and induces apoptosis via activating the mitochondrial pathways

artículo científico publicado en 2007

Auranofin-mediated inhibition of PI3K/AKT/mTOR axis and anticancer activity in non-small cell lung cancer cells

artículo científico publicado en 2015

Autologous Stem Cell Transplantation Improves Survival For High Risk Cardiac Amyloidosis ⬇️

scholarly article

Autologous hematopoietic stem cell transplantation may reverse renal failure in patients with multiple myeloma.

artículo científico publicado en 2009

B-Cell Lymphoma Patient-Derived Xenograft Models Enable Drug Discovery and Are a Platform for Personalized Therapy

artículo científico publicado en 2017

B-cell receptor-mediated NFATc1 activation induces IL-10/STAT3/PD-L1 signaling in diffuse large B-cell lymphoma

artículo científico publicado en 2018

Baseline Peripheral Neuropathy Does Not Impact the Efficacy and Tolerability of the Novel Proteasome Inhibitor Carfilzomib (CFZ): Results of a Subset Analysis of a Phase 2 Trial In Patients with Relapsed and Refractory Multiple Myeloma (R/R MM) ⬇️

artículo científico publicado en 2010

Better quality of response to lenalidomide plus dexamethasone is associated with improved clinical outcomes in patients with relapsed or refractory multiple myeloma

artículo científico publicado en 2010

Biological Significance of the Immumoproteasome Subunits Mecl-1 and LMP-2 in Diffuse Large B-Cell Lymphoma. ⬇️

artículo científico publicado en 2012

Blastoid Mantle Cell Lymphoma

scientific article published on 05 August 2020

Blockade of interleukin-6 signalling with siltuximab enhances melphalan cytotoxicity in preclinical models of multiple myeloma

artículo científico publicado en 2011

Blood Transfusion and Erythropoiesis Stimulating Agents (ESAs) Use In Patients with Diffuse Large B-Cell Lymphoma (DLBCL) ⬇️

artículo científico publicado en 2010

Bortezomib Resistance Is Mediated by Increased Signaling through the Insulin-Like Growth Factor-1/Akt Axis. ⬇️

artículo científico publicado en 2009

Bortezomib-Containing Regimens for Multiple Myeloma Maintenance Therapy: a Meta-Analysis ⬇️

scholarly article

Bortezomib-based consolidation or maintenance therapy for multiple myeloma: a meta-analysis

scientific article published on 06 March 2020

Bortezomib-cyclophosphamide-dexamethasone for relapsing multiple myeloma

artículo científico publicado en 2012

Bortezomib-resistant nuclear factor κB expression in stem-like cells in mantle cell lymphoma

artículo científico publicado en 2011

Bridging therapy prior to axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma

artículo científico publicado en 2020

CCND1 mutations increase protein stability and promote ibrutinib resistance in mantle cell lymphoma

artículo científico publicado en 2016

CD10-positive mantle cell lymphoma: clinicopathologic and prognostic study of 30 cases.

artículo científico publicado en 2017

CD200 expression in mantle cell lymphoma identifies a unique subgroup of patients with frequent IGHV mutations, absence of SOX11 expression, and an indolent clinical course

artículo científico publicado en 2017

CD23 expression in mantle cell lymphoma is associated with CD200 expression, leukemic non-nodal form, and a better prognosis

scientific article published on 02 May 2019

CD4⁺ T cells play a crucial role for lenalidomide in vivo anti-tumor activity in murine multiple myeloma

artículo científico publicado en 2015

CD5 Negative Mantle Cell Lymphoma: Clinicopathologic Correlations and Outcome in 58 Cases ⬇️

artículo científico publicado en 2016

CD5-negative Mantle Cell Lymphoma: Clinicopathologic Correlations and Outcome in 58 Patients

artículo científico publicado en 2019

CUDC-907: An Oral HDAC/PI3K Dual Inhibitor with Strong Preclinical Efficacy in MCL Model ⬇️

artículo científico publicado en 2016

Calcium blockers decrease the bortezomib resistance in mantle cell lymphoma via manipulation of tissue transglutaminase activities

artículo científico publicado en 2012

Cardiovascular events in patients treated with chimeric antigen receptor t-cell therapy for aggressive B-cell lymphoma

artículo científico publicado en 2021

Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma.

artículo científico publicado en 2016

Carfilzomib, An Irreversible Proteasome Inhibitor, Induces Long-Term Growth Inhibition of Mantle Cell Lymphoma In Vivo, ⬇️

scholarly article

Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma

article

Carfilzomib, a Second-Generation Proteasome Inhibitor, In Combination With The Btk Inhibitor Ibrutinib As a Novel Therapeutic Regimen For Treating Double Hit DLBCL ⬇️

artículo científico publicado en 2013

Carfilzomib: High Single Agent Response Rate with Minimal Neuropathy Even In High-Risk Patients ⬇️

artículo científico publicado en 2010

Challenges and Opportunities for High-grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangement (Double-hit Lymphoma).

artículo científico publicado en 2018

Characteristics, Outcome and Pattern of Mutations in Patients with Follicular Lymphoma Who Progressed on BTK Inhibitors (Ibrutinib and acalabrutinib) ⬇️

artículo científico publicado en 2016

Characteristics, management, and outcomes of patients with follicular dendritic cell sarcoma.

artículo científico publicado en 2017

Chemotherapy and survival for patients with multiple myeloma: findings from a large nationwide and population-based cohort

artículo científico publicado en 2007

Chemotherapy-Free Induction with Ibrutinib-Rituximab Followed By Shortened Cycles of Chemo-Immunotherapy Consolidation in Young, Newly Diagnosed Mantle Cell Lymphoma Patients: A Phase II Clinical Trial ⬇️

artículo científico publicado en 2016

Clinical activity of carfilzomib correlates with inhibition of multiple proteasome subunits: application of a novel pharmacodynamic assay

artículo científico publicado en 2016

Clinical and Genomic Characteristics in De Novo Blastoid/Pleomorphic (dnMCL) and Transformed Blastoid/Pleomorphic (t-MCL) Mantle Cell Lymphoma (MCL) in the Ibrutinib Era: Comprehensive Analysis of 168 Patients ⬇️

scholarly article

Clinical and radiologic correlates of neurotoxicity after axicabtagene ciloleucel in large B-cell lymphoma

artículo científico publicado en 2020

Clinical outcomes of a novel combination of lenalidomide and rituximab followed by stem cell transplantation for relapsed/refractory aggressive B-cell non-hodgkin lymphoma

artículo científico publicado en 2014

Clinico-Pathological Characteristics, Treatments and Outcomes of Patients with Dendritic Cell Sarcoma (DS) ⬇️

artículo científico publicado en 2015

Clinicopathological characteristics, outcomes and pattern of mutations in patients with follicular lymphoma who progressed on Bruton tyrosine kinase inhibitors.

artículo científico publicado en 2017

Combination of atiprimod and the proteasome inhibitor bortezomib induces apoptosis of mantle cell lymphoma in vitro and in vivo

artículo científico publicado en 2011

Comparative Effectiveness of Chemotherapy, Rituximab, and Bendamustine in Medicare Beneficiaries With Mantle-Cell Lymphoma

artículo científico publicado en 2019

Composite mantle cell lymphoma and chronic lymphocytic leukemia/small lymphocytic lymphoma: a clinicopathologic and molecular study

artículo científico publicado en 2012

Constitutive Activation of p38 MAPK in Myeloma Cells Contributes to Myeloma-Induced Osteolytic Bone Lesions. ⬇️

artículo científico publicado en 2009

Curability of multiple myeloma

artículo científico publicado en 2012

Current regimens and novel agents for mantle cell lymphoma

artículo científico publicado en 2014

Current status and future directions in the treatment of multiple myeloma

artículo científico publicado en 2007

Current trials for frontline therapy of mantle cell lymphoma

artículo científico publicado en 2018

Deletion of the short arm of chromosome 1 (del 1p) is a strong predictor of poor outcome in myeloma patients undergoing an autotransplant

scientific article published on 16 July 2007

Developing Novel Therapeutic Strategies to Overcome Ibrutinib Resistance in Mantle Cell Lymphoma ⬇️

scholarly article

Dickkopf-1 (DKK1) is a widely expressed and potent tumor-associated antigen in multiple myeloma

artículo científico publicado en 2007

Dose adjusted-EPOCH-R and mediastinal disease may improve outcomes for patients with gray-zone lymphoma

artículo científico publicado en 2016

Dose-related safety and immunogenicity of baculovirus-expressed trivalent influenza vaccine: a double-blind, controlled trial in adult patients with non-Hodgkin B cell lymphoma

artículo científico publicado en 2006

Double hit lymphoma: the MD Anderson Cancer Center clinical experience.

artículo científico publicado en 2014

Dual inhibition of PI3K signaling and histone deacetylation halts proliferation and induces lethality in mantle cell lymphoma

artículo científico publicado en 2018

Durable response with single-agent acalabrutinib in patients with relapsed or refractory mantle cell lymphoma

artículo científico publicado en 2019

Effect of long-term storage in TRIzol on microarray-based gene expression profiling

artículo científico publicado en 2010

Effectiveness of Lenalidomide in Patients with Mantle Cell Lymphoma Who Relapsed/Progressed after or Were Refractory/Intolerant to Ibrutinib: The MCL-004 Study ⬇️

artículo científico publicado en 2016

Effects of Rituximab, Bortezomib, and Bendamustine on the Survival in Medicare Beneficiaries with Mantle Cell Lymphoma

scholarly article

Efficacy and Safety of Carfilzomib, Lenalidomide, and Dexamethasone Vs Lenalidomide and Dexamethasone in Patients with Relapsed Multiple Myeloma Based on Cytogenetic Risk Status: Subgroup Analysis from the Phase 3 Study Aspire (NCT01080391) ⬇️

scholarly article

Efficacy of venetoclax in high risk relapsed mantle cell lymphoma (MCL) - outcomes and mutation profile from venetoclax resistant MCL patients

scientific article published on 02 April 2020

Electroacupuncture for thalidomide/bortezomib-induced peripheral neuropathy in multiple myeloma: a feasibility study

artículo científico publicado en 2014

Enhancing intracellular accumulation and target engagement of PROTACs with reversible covalent chemistry

artículo científico publicado en 2020

Ethnic variations in diagnosis, treatment, socioeconomic status, and survival in a large population-based cohort of elderly patients with non-Hodgkin lymphoma.

artículo científico publicado en 2008

Everolimus for patients with mantle cell lymphoma refractory to or intolerant of bortezomib: multicentre, single-arm, phase 2 study

artículo científico publicado en 2014

Evidence of a role for activation of Wnt/beta-catenin signaling in the resistance of plasma cells to lenalidomide

artículo científico publicado en 2010

Expression of B7-H1 in Mantle Cell Lymphoma Leads to Inhibition of T Cell Response to Tumor Cells ⬇️

artículo científico publicado en 2011

Expression of sulfotransferase SULT1A1 in cancer cells predicts susceptibility to the novel anticancer agent NSC-743380

artículo científico publicado en 2015

Feasibility of autologous hematopoietic stem cell transplant in patients aged ≥70 years with multiple myeloma

artículo científico publicado en 2011

Final Results of a Phase 1/2a, Dose Escalation Study of Pvx-410 Multi-Peptide Cancer Vaccine in Patients with Smoldering Multiple Myeloma (SMM) ⬇️

scholarly article

Final Results of a Phase I/II Trial of the Combination of Concurrent Lenalidomide, Thalidomide and Dexamethasone in Patients with Relapsed and/or Refractory Myeloma ⬇️

artículo científico publicado en 2012

Frontline antibiotic therapy for early-stage Helicobacter pylori-negative gastric MALT lymphoma

scientific article published on 06 March 2019

Gene mutations and actionable genetic lesions in mantle cell lymphoma.

artículo científico publicado en 2016

Gene mutations in primary tumors and corresponding patient-derived xenografts derived from non-small cell lung cancer

artículo científico publicado en 2014

Genetic and Molecular Characterization of Ibrutinib-Resistant Mantle Cell Lymphoma: Designing Innovative Therapeutic Strategies ⬇️

scholarly article

Guideline for the management of mantle cell lymphoma

artículo científico publicado en 2018

HDM-2 inhibition suppresses expression of ribonucleotide reductase subunit M2, and synergistically enhances gemcitabine-induced cytotoxicity in mantle cell lymphoma

artículo científico publicado en 2011

Hematology oncology practice in the Asia-Pacific APHCON survey results from the 6th international hematologic malignancies conference: bridging the gap 2015, Beijing, China

artículo científico publicado en 2017

High Dose Therapy Improves Survival in Systemic Light Chain Amyloidosis: 14 Year Follow up ⬇️

scholarly article

High frequencies of response after limited primary therapy for multiple myeloma

scientific article published on 20 December 2012

High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine

artículo científico publicado en 2005

High ten-year remission rates following rituximab, fludarabine, mitoxantrone and dexamethasone (R-FND) with interferon maintenance in indolent lymphoma: Results of a randomized Study

artículo científico publicado en 2017

High-Dose Gemcitabine Combined With Busulfan and Melphalan (Gem/Bu/Mel) With Autologous Stem-Cell Transplant (ASCT) In Refractory and Relapsed Myeloma ⬇️

scholarly article

High-Risk Mantle Cell Lymphoma: Definition, Current Challenges, and Management

artículo científico publicado en 2020

Human C-reactive protein binds activating Fcgamma receptors and protects myeloma tumor cells from apoptosis

artículo científico publicado en 2007

Ibrutinib for the treatment of relapsed/refractory mantle cell lymphoma: extended 3.5-year follow up from a pooled analysis

artículo científico publicado en 2018

Ibrutinib-Resistant Mantle Cell Lymphoma Undergoes Metabolic Reprogramming Towards Oxphos ⬇️

artículo científico publicado en 2018

Ibrutinib-related atrial fibrillation in patients with mantle cell lymphoma

scientific article published on 18 April 2016

Ibrutinib: a strong candidate for the future of mantle cell lymphoma treatment

artículo científico publicado en 2013

Immunomodulation therapy with lenalidomide in follicular, transformed and diffuse large B cell lymphoma: current data on safety and efficacy

artículo científico publicado en 2013

Immunotherapy in mantle cell lymphoma: anti-CD20-based therapy and beyond

artículo científico publicado en 2008

Impairment of filgrastim-induced stem cell mobilization after prior lenalidomide in patients with multiple myeloma

artículo científico publicado en 2009

In vitro and in vivo therapeutic efficacy of carfilzomib in mantle cell lymphoma: targeting the immunoproteasome

artículo científico publicado en 2013

Incidence trends of mantle cell lymphoma in the United States between 1992 and 2004.

artículo científico publicado en 2008

Increase in survival for patients with mantle cell lymphoma in the era of novel agents in 1995-2013: Findings from Texas and national SEER areas

artículo científico publicado en 2018

Inhibition of Interleukin-6 Signaling with CNTO 328 Sensitizes Plasma Cell Dyscrasias to the Effects of Melphalan in Association with Suppression of Signaling through Protein Kinase B/Akt. ⬇️

scholarly article

Integrated stress response and immune cell infiltration in an ibrutinib-refractory mantle cell lymphoma patient following ONC201 treatment

artículo científico publicado en 2018

Interim Results of an International, Multicenter, Phase 2 Study of Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765), in Relapsed or Refractory Mantle Cell Lymphoma (MCL): Durable Efficacy and Tolerability with Longer Follow-up ⬇️

artículo científico publicado en 2012

Interrogating B cell signaling pathways: A quest for novel therapies for mantle cell lymphoma

artículo científico publicado en 2019

Involvement of tumor-associated macrophage activation in vitro during development of a novel mantle cell lymphoma cell line, PF-1, derived from a typical patient with relapsed disease

artículo científico publicado en 2014

KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma

artículo científico publicado en 2020

KTE-X19, an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, in Patients (Pts) with Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL): Results of the Phase 2 ZUMA-2 Study ⬇️

scholarly article

Lenalidomide (L) in Combination with Dexamethasone (D) Improves Survival and Time to Progression in Elderly Patients (pts) with Relapsed or Refractory (rel/ref) Multiple Myeloma (MM). ⬇️

artículo científico publicado en 2006

Lenalidomide Plus Rituximab for Relapsed or Refractory Diffuse Large B-Cell, Follicular and Transformed Lymphoma: Final Data Analysis of a Phase 2 Trial ⬇️

scholarly article

Lenalidomide and Rituximab for Untreated Indolent Lymphoma: Final Results of a Phase II Study ⬇️

scholarly article

Lenalidomide in Combination with Dexamethasone Was More Effective Than Dexamethasone in Patients Who Have Received Prior Thalidomide for Relapsed or Refractory Multiple Myeloma. ⬇️

artículo científico publicado en 2006

Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial

artículo científico publicado en 2012

Lenalidomide in relapsed or refractory mantle cell lymphoma: overview and perspective

artículo científico publicado en 2014

Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America

artículo científico publicado en 2007

Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure

artículo científico publicado en 2008

Lenalidomide plus rituximab (R2 ) in previously untreated marginal zone lymphoma: subgroup analysis and long-term follow-up of an open-label phase 2 trial

scientific article published on 28 March 2019

Lenalidomide synergizes with dexamethasone to induce growth arrest and apoptosis of mantle cell lymphoma cells in vitro and in vivo ⬇️

artículo científico publicado el 2 de noviembre de 2010

Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study

artículo científico publicado en 2020

Long-Term Follow-up of Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Mantle Cell Lymphoma ⬇️

artículo científico publicado en 2018

Long-Term Remissions of Patients With Follicular Lymphoma Grade 3 Treated With R-CHOP.

artículo científico publicado en 2017

Longitudinal single-cell profiling reveals molecular heterogeneity and tumor-immune evolution in refractory mantle cell lymphoma

artículo científico publicado en 2021

Loss of HDAC11 Promotes Myeloid-Derived Suppressor Cells Inhibition of T Cell Function in a Murine Lymphoma Microenvironment ⬇️

artículo científico publicado en 2018

Low-dose radiation (4 Gy) with/without concurrent chemotherapy is highly effective for relapsed, refractory mantle cell lymphoma

scientific article published on 01 July 2019

Luteinizing Hormone-Releasing Hormone (LHRH)-I antagonist cetrorelix inhibits myeloma cell growth in vitro and in vivo

artículo científico publicado en 2010

MYC rearrangement but not extra MYC copies is an independent prognostic factor in patients with mantle cell lymphoma

scientific article published on 09 April 2020

Macrophages are an abundant component of myeloma microenvironment and protect myeloma cells from chemotherapy drug-induced apoptosis

artículo científico publicado en 2009

Magic year for multiple myeloma therapeutics: Key takeaways from the ASH 2015 annual meeting

artículo científico publicado en 2016

Management Strategies and Outcomes for Very Elderly Patients with Diffuse Large B-Cell Lymphoma (DLBCL) ⬇️

artículo científico publicado en 2015

Management of a patient with mantle cell lymphoma who developed severe neurotoxicity after chimeric antigen receptor T-cell therapy in ZUMA-2

scientific article published on 01 October 2020

Management strategies and outcomes for very elderly patients with diffuse large B-cell lymphoma.

artículo científico publicado en 2016

Mantle Cell Lymphoma Cells Express B7 Family Molecules and B7-H1 Expression Are up-Regulated After LPS Exposure Via MEK-Dependent and PI3K/Akt-Dependent Pathways In Mantle Cell Lymphoma Cells ⬇️

artículo científico publicado en 2010

Mantle cell lymphoma: 2019 update on the diagnosis, pathogenesis, prognostication, and management

scientific article published on 19 April 2019

Mechanistic studies on the synergistic cytotoxicity of the nucleoside analogs gemcitabine and clofarabine in multiple myeloma: relevance of p53 and its clinical implications

artículo científico publicado en 2013

Metabolic Profiling Identifies De Novo Nucleotide Synthesis As a Potential Metabolic Vulnerability for Targeted Therapy Against Mantle Cell Lymphoma ⬇️

scholarly article

Metabolic reprogramming toward oxidative phosphorylation identifies a therapeutic target for mantle cell lymphoma

scientific article published on 01 May 2019

Molecular Profiling plus In Vitro and In Vivo Drug Efficacy Analyses Identifies Novel Treatments to Overcome Ibrutinib Resistance in Mantle Cell Lymphoma

scholarly article

Molecular Signatures of Tumor-Initiating Cells Unveil Wnt Pathway As a Therapeutic Target in Mantle Cell Lymphoma ⬇️

scholarly article

Multiple myeloma, painful neuropathy, acupuncture?

artículo científico publicado en 2009

Myeloma cell line-derived, pooled heat shock proteins as a universal vaccine for immunotherapy of multiple myeloma

artículo científico publicado en 2009

NF-κB signaling and its relevance to the treatment of mantle cell lymphoma.

artículo científico publicado en 2018

NR4A1 inhibition synergizes with ibrutinib in killing mantle cell lymphoma cells

artículo científico publicado en 2017

Novel CRM-1 Inhibitors for Therapy In Mantle Cell Lymphoma ⬇️

scholarly article

Novel Combination Of Lenalidomide-Rituximab Provides An Effective Bridge To Stem Cell Transplantation In Relapsed and/Or Refractory Aggressive B-Cell Non-Hodgkin’s Lymphomas: A Single Center Experience ⬇️

artículo científico publicado en 2013

Novel PI3K Inhibitor Compound A Induces Myeloma Cell Apoptosis and Shows Synergistic Cytotoxicity with Dexamethasone In Multiple Myeloma ⬇️

scholarly article

Novel selective inhibitors of nuclear export CRM1 antagonists for therapy in mantle cell lymphoma

artículo científico publicado en 2012

Nuclear translocation of B-cell-specific transcription factor, BACH2, modulates ROS mediated cytotoxic responses in mantle cell lymphoma

artículo científico publicado en 2013

Observational study of lenalidomide in patients with mantle cell lymphoma who relapsed/progressed after or were refractory/intolerant to ibrutinib (MCL-004).

artículo científico publicado en 2017

Osteoblastic niche supports the growth of quiescent multiple myeloma cells

artículo científico publicado en 2014

Outcome of Patients With Nonsecretory Multiple Myeloma After Autologous Hematopoietic Stem Cell Transplantation.

artículo científico publicado en 2015

Outcomes in 370 patients with mantle cell lymphoma treated with ibrutinib: a pooled analysis from three open-label studies

artículo científico publicado en 2017

Outcomes, Causes of Discontinuation and Mutation Profile of Patients with Mantle Cell Lymphoma Who Progressed on Acalabrutinib ⬇️

artículo científico publicado en 2018

PILLAR-1: Preliminary Results of a Phase II Study of mTOR Inhibitor Everolimus In Patients with Mantle Cell Lymphoma (MCL) Who Are Refractory or Intolerant to Bortezomib ⬇️

scholarly article

PRMT5 is upregulated by B-cell receptor signaling and forms a positive-feedback loop with PI3K/AKT in lymphoma cells

artículo científico publicado en 2019

Paramount therapy for young and fit patients with mantle cell lymphoma: strategies for front-line therapy.

artículo científico publicado en 2018

Patient-Derived Xenograft Model in B-Cell Lymphoma: A Platform for a Personalized Clinical Trial ⬇️

scholarly article

Pegylated liposomal doxorubicin replacing conventional doxorubicin in standard R-CHOP chemotherapy for elderly patients with diffuse large B-cell lymphoma: an open label, single arm, phase II trial

artículo científico publicado en 2014

Peripheral Absolute Neutrophil, Mmonocyte and Lymphocyte Counts and Clinical Ooutcome in Diffuse Large B-Cell Lymphoma ⬇️

artículo científico publicado en 2014

Phase 1 Study Of The Novel Kinesin Spindle Protein Inhibitor ARRY-520 + Carfilzomib (Car) In Patients With Relapsed and/Or Refractory Multiple Myeloma (RRMM) ⬇️

scholarly article

Phase 1 Study of the Novel Kinesin Spindle Protein Inhibitor ARRY-520 + Carfilzomib in Patients with Relapsed and/or Refractory Multiple Myeloma ⬇️

artículo científico publicado en 2012

Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patients

artículo científico publicado en 2014

Phase 1/1b Study of the Efficacy and Safety of the Combination of Panobinostat + Carfilzomib in Patients with Relapsed and/or Refractory Multiple Myeloma ⬇️

scholarly article

Phase 2 dose-expansion study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma

artículo científico publicado en 2013

Phase 2 trial of bortezomib in combination with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with bortezomib, rituximab, methotrexate, and cytarabine for untreated mantle cell lymphoma.

artículo científico publicado en 2018

Phase 2 trial of rituximab plus hyper-CVAD alternating with rituximab plus methotrexate-cytarabine for relapsed or refractory aggressive mantle cell lymphoma

artículo científico publicado en 2008

Phase I trial of bortezomib in combination with rituximab‐HyperCVAD alternating with rituximab, methotrexate and cytarabine for untreated aggressive mantle cell lymphoma ⬇️

artículo científico publicado el 5 de agosto de 2010

Phase I/II study of high dose pomalidomide with G-CSF support and dexamethasone in patients with relapsed/refractory multiple myeloma

scientific article published on 10 May 2020

Phase II Study of Bortezomib in Combination with Cyclophosphamide and Rituximab for Relapsed or Refractory Mantle Cell Lymphoma

artículo científico publicado en 2017

Phase II Trial Of Bortezomib In Combination With Fractionated Cyclophosphamide and Rituximab (BCR) For Relapsed/Refractory Mantle Cell Lymphoma (MCL) ⬇️

artículo científico publicado en 2013

Phase II study of HCVIDD/MA in patients with newly diagnosed peripheral T-cell lymphoma

artículo científico publicado en 2015

Phase II study of an AKT inhibitor MK2206 in patients with relapsed or refractory lymphoma

artículo científico publicado en 2015

Phase II study of denileukin diftitox for relapsed/refractory B-Cell non-Hodgkin's lymphoma

artículo científico publicado en 2004

Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma

artículo científico publicado en 2004

Phase II study of yttrium-90-ibritumomab tiuxetan in patients with relapsed or refractory mantle cell lymphoma

artículo científico publicado en 2009

Phase II trial of the combination of denileukin diftitox and rituximab for relapsed/refractory B-cell non-Hodgkin lymphoma

artículo científico publicado en 2007

Phase Ib dose-escalation study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma

artículo científico publicado en 2013

Pillar-1: Multicenter Phase 2 Study of Everolimus for Patients with Mantle Cell Lymphoma Who Are Refractory or Intolerant to Bortezomib. ⬇️

scholarly article

Pleiotropic Action of Novel Bruton's Tyrosine Kinase Inhibitor BGB-3111 in Mantle Cell Lymphoma

artículo científico publicado en 2018

Pooled Safety Analysis From Phase (Ph) 1 and 2 Studies of Carfilzomib (CFZ) In Patients with Relapsed and/or Refractory Multiple Myeloma (MM) ⬇️

artículo científico publicado en 2010

Pre-treatment maximum standardized uptake value predicts outcome after frontline therapy in patients with advanced stage follicular lymphoma

artículo científico publicado en 2019

Predictors of prolonged survival after allogeneic hematopoietic stem cell transplantation for multiple myeloma

artículo científico publicado en 2012

Pretreatment SUVmax may influence the clinical benefit of BR over R-CHOP in patients with previously untreated FL

artículo científico publicado en 2020

Prognostic significance of baseline peripheral absolute neutrophil, monocyte and serum β2-microglobulin level in patients with diffuse large b-cell lymphoma: a new prognostic model.

artículo científico publicado en 2016

Prospective isolation of clonogenic mantle cell lymphoma-initiating cells

artículo científico publicado en 2010

Prospective phase II study of rituximab with alternating cycles of hyper-CVAD and high-dose methotrexate with cytarabine for young patients with high-risk diffuse large B-cell lymphoma

artículo científico publicado en 2013

Radiation therapy is an effective modality in the treatment of mantle cell lymphoma, even in heavily pretreated patients.

artículo científico publicado en 2014

Rapid Control of Previously Untreated Multiple Myeloma with Bortezomib-Thalidomide-Dexamethasone Followed by Early Intensive Therapy. ⬇️

artículo científico publicado en 2005

Reduced-intensity allogeneic hematopoietic stem cell transplantation for relapsed multiple myeloma

artículo científico publicado en 2010

Regulation of Fas-mediated Apoptosis in B-Cell Lymphomas by Nucleolin. ⬇️

scholarly article

Repurposing auranofin to treat TP53-mutated or PTEN-deleted refractory B-cell lymphoma

scientific article published on 28 November 2019

Research of miR-30b in Cisplatin Resistance of Human NK/T Cell Lymphoma Lines SNK-6 and YTS Cells By Targeting CCL22 ⬇️

scholarly article

Response and progression-free survival according to planned treatment duration in patients with relapsed multiple myeloma treated with carfilzomib, lenalidomide, and dexamethasone (KRd) versus lenalidomide and dexamethasone (Rd) in the phase III ASP

artículo científico publicado en 2018

Results of Bortezomib (BTZ) Therapy for Myeloma (MM) Patients Relapsing after an Allogeneic Transplant. Preliminary Results Show Efficacy without Induction of GVHD. ⬇️

scholarly article

Results of PX-171-003-A1, An Open-Label, Single-Arm, Phase 2 (Ph 2) Study of Carfilzomib (CFZ) In Patients (pts) with Relapsed and Refractory Multiple Myeloma (MM) ⬇️

artículo científico publicado en 2010

Retrospective Comparison of Transplant Outcomes in Patients with Multiple Myeloma According to Induction Therapy with Thalidomide/Dexamethasone (TD) with or without Bortezomib (VTD). ⬇️

artículo científico publicado en 2007

Rituximab (R) + Hypercvad Alternating with R-Methotrexate/Cytarabine after 9 Years: Continued High Rate of Failure-Free Survival in Untreated Mantle Cell Lymphoma (MCL) ⬇️

scholarly article

Role of the microenvironment in mantle cell lymphoma: IL-6 is an important survival factor for the tumor cells

artículo científico publicado en 2012

SOX11-negative Mantle Cell Lymphoma: Clinicopathologic and Prognostic Features of 75 Patients

scientific article published on 01 May 2019

Safety and Efficacy of Acalabrutinib Plus Bendamustine and Rituximab (BR) in Patients with Treatment-Naive (TN) or Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL) ⬇️

scholarly article

Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial

artículo científico publicado en 2014

Safety and efficacy of once-per-cycle pegfilgrastim in support of ABVD chemotherapy in patients with Hodgkin lymphoma.

artículo científico publicado en 2006

Safety of Axicabtagene Ciloleucel CD19 CAR T-Cell Therapy in Elderly Patients with Relapsed or Refractory Large B-Cell Lymphoma ⬇️

artículo científico publicado en 2018

Safety, Efficacy, and Determination of the Recommended Phase 2 Dose for the Oral Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) ⬇️

scholarly article

Salvage Autologous or Allogeneic Stem Cell Transplantation After the Failure of First Autograft in Patients with Multiple Myeloma. ⬇️

artículo científico publicado en 2009

Second Cancers in a Patient with Gastric MALT Lymphoma

artículo científico publicado en 2020

Selective Inhibitor Of Nuclear Exports (SINE) KPT-330 In Combination With The Novel Proteasome Inhibitor Carfilzomib As a Novel Therapeutic Regimen For Treating Aggressive B-Cell Lymphomas ⬇️

scholarly article

Selective antitumor activity of ibrutinib in EGFR-mutant non-small cell lung cancer cells

artículo científico publicado en 2014

Selective inhibition of nuclear export with selinexor in patients with non-Hodgkin lymphoma.

artículo científico publicado en 2017

Serum free light chain reduction correlates with response and progression-free survival following carfilzomib therapy in relapsed/refractory multiple myeloma

artículo científico publicado en 2015

Seven Year Follow up and Comparison of Dosing Strategies from the Pivotal Phase II Clinical Trial of Lenalidomide Plus Rituximab (R2) in Previously Untreated Follicular Lymphoma ⬇️

scholarly article

Simultaneous Inhibition of BCL-2 and PI3K Signaling Overcomes Ibrutinib Resistance in Mantle Cell Lymphoma ⬇️

scholarly article

Single nucleotide variation in the TP53 3' untranslated region in diffuse large B-cell lymphoma treated with rituximab-CHOP: a report from the International DLBCL Rituximab-CHOP Consortium Program

artículo científico publicado en 2013

Single-Agent Ibrutinib Demonstrates Safety and Durability of Response at 2 Years Follow-up in Patients with Relapsed or Refractory Mantle Cell Lymphoma: Updated Results of an International, Multicenter, Open-Label Phase 2 Study ⬇️

artículo científico publicado en 2014

Smoldering mantle cell lymphoma.

artículo científico publicado en 2017

Strategic therapeutic targeting to overcome venetoclax resistance in aggressive B-cell lymphomas.

artículo científico publicado en 2018

Survival Disparities Between African-American and Caucasian Patients with Multiple Myeloma Are Blunted in the Era of Novel Therapeutics and Autologous Stem Cell Transplantation. ⬇️

artículo científico publicado en 2009

Survival Outcomes of Patients Receiving Thalidomide-Dexamethasone for Previously Untreated Multiple Myeloma. ⬇️

artículo científico publicado en 2006

Synergistic antitumor effects of lenalidomide and rituximab on mantle cell lymphoma in vitro and in vivo

artículo científico publicado en 2009

Targeting BCR Activated STAT3 By Ibrutinib In Mantle Cell Lymphoma ⬇️

artículo científico publicado en 2013

Targeting CDK9 Dramatically Potentiates ABT-737-Induced Apoptosis in Human Multiple Myeloma Cells through a Bim-Dependent Mechanism. ⬇️

scholarly article

Targeting Oxphos Pathway Against Ibrutinib Resistance to Mantle Cell Lymphoma ⬇️

scholarly article

Targeting Wnt pathway in mantle cell lymphoma-initiating cells.

artículo científico publicado en 2015

Targeting beta2-microglobulin for induction of tumor apoptosis in human hematological malignancies

artículo científico publicado en 2006

Targeting cell surface β2 -microglobulin by pentameric IgM antibodies

artículo científico publicado en 2011

Targeting human B-cell malignancies through Ig light chain-specific cytotoxic T lymphocytes

artículo científico

Targeting the Spleen Tyrosine Kinase with Fostamatinib as a Strategy against Waldenström Macroglobulinemia

artículo científico publicado en 2015

Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma.

artículo científico publicado en 2012

Temporal and geographic variations of Waldenstrom macroglobulinemia incidence: a large population-based study.

artículo científico publicado en 2011

Ten-year follow-up after intense chemoimmunotherapy with Rituximab-HyperCVAD alternating with Rituximab-high dose methotrexate/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma

artículo científico publicado en 2010

Thalidomide with or without dexamethasone for refractory or relapsing multiple myeloma

artículo científico publicado en 2003

Thalidomide-dexamethasone as primary therapy for advanced multiple myeloma

artículo científico publicado en 2005

The CD20-specific engineered toxin antibody MT-3724 exhibits lethal effects against mantle cell lymphoma.

artículo científico publicado en 2018

The Efficacy and Safety of Immunomodulatory Drugs in Multiple Myeloma Maintenance Therapy: Results of a Meta-Analysis ⬇️

scholarly article

The HSP90-MYC-CDK9 network drives therapeutic resistance in mantle cell lymphoma

artículo científico publicado en 2024

The Identification of Novel Therapies for the Treatment of Follicular Dendritic Cell Sarcoma ⬇️

artículo científico publicado en 2015

The Risk of Central Nervous System (CNS) Relapses in Patients with Peripheral T-Cell Lymphoma ⬇️

artículo científico publicado en 2016

The Role Of Mir-155 In Controlling Key Growth and Survival Pathways In ABC-Subtype DLBCL ⬇️

artículo científico publicado en 2013

The Survival Outcome of the Patients with Relapsed/Refractory Anaplastic Large-Cell Lymphoma ⬇️

scholarly article

The Survival Outcome of the Patients with Relapsed/Refractory PTCL-NOS and AITL ⬇️

artículo científico publicado en 2015

The Tumor Microenvironment in Mantle Cell Lymphoma (MCL): Novel Targets to Overcome Chemo-Resistance in MCL ⬇️

artículo científico publicado en 2014

The risk of central nervous system relapses in patients with peripheral T-cell lymphoma.

artículo científico publicado en 2018

The survival outcome of patients with relapsed/refractory peripheral T-cell lymphoma-not otherwise specified and angioimmunoblastic T-cell lymphoma.

artículo científico publicado en 2016

Time to Treatment Failure (TTF) and FLIPI Correlate Well with Survival and Are Independent Variables in Stage IV Indolent Follicular Lymphomas (IFL). ⬇️

scholarly article

Transcriptional programming drives Ibrutinib-resistance evolution in mantle cell lymphoma

artículo científico publicado en 2021

Trend and Geographic Variations in the Incidence of Mantle Cell Lymphoma in the United States over 30 Years from 1975 to 2004. ⬇️

artículo científico publicado en 2007

Trend and Geographic Variations in the Incidence of Waldenstrom’s Macroglobulinemia in the United States over 17 Years from 1988 to 2004. ⬇️

artículo científico publicado en 2007

Trends and variations in mantle cell lymphoma incidence from 1995 to 2013: A comparative study between Texas and National SEER areas

artículo científico publicado en 2017

Ultra-low-dose radiotherapy for definitive management of ocular adnexal B-cell lymphoma

artículo científico publicado en 2017

Ultra-low-dose radiotherapy for definitive management of ocular adnexal B-cell lymphoma

scientific article published on 21 February 2018

Ultra-low-dose radiotherapy for definitive management of ocular adnexal B-cell lymphoma

artículo científico publicado en 2019

Unification of de novo and acquired ibrutinib resistance in mantle cell lymphoma

artículo científico publicado en 2017

Updated Results of a Phase 1/2a, Dose Escalation Study of Pvx-410 Multi-Peptide Cancer Vaccine in Patients with Smoldering Multiple Myeloma (SMM) ⬇️

artículo científico publicado en 2015

Updated Safety and Activity of the Investigational Bruton Tyrosine Kinase Inhibitor Zanubrutinib (BGB-3111) in Patients with Mantle Cell Lymphoma ⬇️

artículo científico publicado en 2018

Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors

artículo científico publicado en 2020

Use of bortezomib in B-cell non-Hodgkin's lymphoma

artículo científico publicado en 2006

Verapamil synergistically enhances cytotoxicity of bortezomib in mantle cell lymphoma via induction of reactive oxygen species production

artículo científico publicado en 2012

iTALK: an R Package to Characterize and Illustrate Intercellular Communication

scholarly article published 4 January 2019

Dominio Público Uruguay está sostenido por:

Acerca de Dominio Público Uruguay

Ayuda